Prof Valerie Speirs

University of Aberdeen

Prof Valerie Speirs obtained a BSc in Zoology from the University of Aberdeen followed by her PhD in Cancer Biology from the University of Glasgow. She became a Fellow of the Royal College of Pathologists in 2007 (published works) and is a Fellow of the Higher Education Authority. Her scientific career has included spells at the Hospital for Sick Children in Toronto, Canada, and the universities of Liverpool, Hull and Leeds. She obtained a Personal Chair in Experimental Pathology & Oncology at the University of Leeds in 2012 and relocated to her alma mater in July 2018 as Chair in Molecular Oncology. Her research portfolio focuses on oestrogen receptor biology, endocrine resistant breast cancer, male breast cancer and developing improved in vitro models of breast cancer to explore the role of the tumour microenvironment.

dont miss

Breast cancer: not just for women

Male breast cancer has been understudied for decades. Men receiving a breast cancer diagnosis are treated in the same way as women, based on assumptions that the underlying biology is identical between genders. I will present an overview of what we have learned about male breast cancer over the last decade, how this differs to breast cancer in women, and outline how some of these findings may be exploited therapeutically.

EVEN MORE SEMINARS

  • Emlyn Samuel: Speaking at the Oncology Convention

    Emlyn Samuel
    Cancer Research UK

    Brexit: getting the best outcome for research and patients

  • Mani Naghibi: Speaking at the Oncology Convention

    Mani Naghibi
    St. Mark's Hospital

    Using nutrition therapies to positively effect cancer treatment outcomes

  • Dr Tom Newsom-Davis: Speaking at the Oncology Convention

    Dr Tom Newsom-Davis
    Leaders in Oncology Care (Part of HCA healthcare UK)

    Immunotherapy and innovative systemic treatments in Oncology

  • Dr Christy Goldsmith: Speaking at the Oncology Convention

    Dr Christy Goldsmith
    Action Radiotherapy

    Improving patient outcomes with Stereotactic Ablative Body Radiotherapy (SABR)

  • Stéfan Halbherr: Speaking at the Oncology Convention

    Stéfan Halbherr
    InnoMedica

    Liposome pipeline addressing unmet medical needs in oncology, imaging, and neurodegeneration